Small cap share analyst and business journalist, Tim Boreham covers companies operating the sleep treatment space. This Stockhead article includes a section on Oventus’ Sleep Treatment Platform.
To read the article, click here.
Leave a Reply
Stockhead – Dr Boreham’s Crucible: how $18bn snore buster ResMed stacks up against ASX sleep minnows
8 February 2019